The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 30, 2014

Filed:

Dec. 22, 2009
Applicants:

Kouji Yokoyama, Yokohama, JP;

Makoto Kimura, Yokohama, JP;

Masashi Tamai, Yokohama, JP;

Yuko Saitoh, Yokohama, JP;

Tomomi Kato, Yokohama, JP;

Yu Ikeda, Yokohama, JP;

Inventors:

Kouji Yokoyama, Yokohama, JP;

Makoto Kimura, Yokohama, JP;

Masashi Tamai, Yokohama, JP;

Yuko Saitoh, Yokohama, JP;

Tomomi Kato, Yokohama, JP;

Yu Ikeda, Yokohama, JP;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 8/49 (2006.01); C07D 233/58 (2006.01); C07D 401/06 (2006.01); A61K 8/44 (2006.01); A61K 8/41 (2006.01); A61K 8/34 (2006.01); C07D 207/404 (2006.01); A61Q 19/02 (2006.01); C07D 213/38 (2006.01); C07D 213/30 (2006.01); C07D 295/03 (2006.01); C07D 207/12 (2006.01); C07D 295/096 (2006.01);
U.S. Cl.
CPC ...
C07D 233/58 (2013.01); A61K 8/4913 (2013.01); A61K 8/494 (2013.01); A61K 8/418 (2013.01); A61K 8/34 (2013.01); C07D 207/404 (2013.01); A61Q 19/02 (2013.01); C07D 401/06 (2013.01); A61K 8/49 (2013.01); A61K 8/4946 (2013.01); C07D 213/38 (2013.01); C07D 213/30 (2013.01); A61K 8/411 (2013.01); C07D 295/03 (2013.01); C07D 207/12 (2013.01); C07D 295/096 (2013.01); A61K 8/41 (2013.01); A61K 8/4926 (2013.01); A61K 8/44 (2013.01);
Abstract

Disclosed is a melanin production inhibitor which has an excellent inhibitory activity on the production of melanin and is highly safe. The melanin production inhibitor is represented by general formula (1) (excluding clotrimazole) and/or a pharmacologically acceptable salt thereof. In the formula, A1, A2 and A3 are independently selected from a hydrogen atom, an aryl group which may have a substituent, and an aromatic heterocyclic group which may have a substituent. At least one of A1, A2 and A3 is selected from the aryl group and the aromatic heterocyclic group, the total number of carbon atoms contained in A1, A2 and A3 is 6 to 50 and, when at least two of A1, A2 and A3 represent the aryl groups or the aromatic heterocyclic groups, the adjacent two aryl or aromatic heterocyclic groups may be bound to each other via an alkyl chain or an alkenyl chain to form a ring; m represents an integer of 0 to 2; X represents a hetero atom, a hydrogen atom, or a carbon atom; R1 and R2 are independently selected from a hydrogen atom and an oxo group. When one of R1 and R2 is an oxo group, the other is not present. R3 is selected from a hydrogen atom, and a Chydrocarbon group in which one or some of hydrogen atoms or carbon atoms may be substituted by a hetero atom or hetero atoms. The number of R3's present in the compound corresponds to X and, when two or more R3's are present, the R3's are independently present and the adjacent two R3's may be bound to each other to form, together with X, a ring, and the terminal of R3 may be bound to a carbon atom to which A1, A2 and A3 are bound, thereby forming a ring.


Find Patent Forward Citations

Loading…